Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label cariprazine safety study in adolescents with schizophrenia
2018-004590-27Phase 3Active
- Sponsor
- Gedeon Richter Plc
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cariprazine in schizophrenia, sponsored by Gedeon Richter Plc. Primary endpoint: Long-term safety and tolerability of cariprazine. Started Aug 2019; status: active.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2018-004590-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004590-27.